Delivering CRISPR to the HIV-1 reservoirs.

CRISPR HIV biodistribution latent viral reservoir vector design

Journal

Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977

Informations de publication

Date de publication:
2024
Historique:
received: 29 02 2024
accepted: 22 04 2024
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 30 5 2024
Statut: epublish

Résumé

Human immunodeficiency virus type 1 (HIV-1) infection is well known as one of the most complex and difficult viral infections to cure. The difficulty in developing curative strategies arises in large part from the development of latent viral reservoirs (LVRs) within anatomical and cellular compartments of a host. The clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9 (CRISPR/Cas9) system shows remarkable potential for the inactivation and/or elimination of integrated proviral DNA within host cells, however, delivery of the CRISPR/Cas9 system to infected cells is still a challenge. In this review, the main factors impacting delivery, the challenges for delivery to each of the LVRs, and the current successes for delivery to each reservoir will be discussed.

Identifiants

pubmed: 38812680
doi: 10.3389/fmicb.2024.1393974
pmc: PMC11133543
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1393974

Informations de copyright

Copyright © 2024 Gurrola, Effah, Sariyer, Dampier, Nonnemacher and Wigdahl.

Déclaration de conflit d'intérêts

The authors declare that the work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Theodore E Gurrola (TE)

Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Center for Molecular Virology and Gene Therapy, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, United States.

Samuel N Effah (SN)

Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Center for Molecular Virology and Gene Therapy, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, United States.

Ilker K Sariyer (IK)

Department of Microbiology, Immunology, and Inflammation and Center for Neurovirology and Gene Editing, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.

Will Dampier (W)

Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Center for Molecular Virology and Gene Therapy, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, United States.

Michael R Nonnemacher (MR)

Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Center for Molecular Virology and Gene Therapy, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, United States.
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.

Brian Wigdahl (B)

Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Center for Molecular Virology and Gene Therapy, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, United States.
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.

Classifications MeSH